Abstract
One of the most important advances in cancer research in recent years is the recognition that killing of tumor cells by anticancer therapies commonly used in the treatment of cancer, e.g. chemotherapy, γ-irradiation, immunotherapy or suicide gene therapy, is predominantly mediated by triggering cell death pathways including apoptosis in cancer cells. Thus, failure to undergo apoptosis may result in treatment resistance of cancers. Understanding the molecular events that regulate apoptosis in response to anticancer therapy and how cancer cells evade apoptotic cell death, provides novel perspectives for a more rational approach to develop molecular targeted therapies for combating cancer.
Keywords: Apoptosis, cancer, cancer therapy, resistance
Current Cancer Therapy Reviews
Title: Apoptosis Signaling Pathways in Anticancer Therapy
Volume: 4 Issue: 1
Author(s): Simone Fulda and Klaus-Michael Debatin
Affiliation:
Keywords: Apoptosis, cancer, cancer therapy, resistance
Abstract: One of the most important advances in cancer research in recent years is the recognition that killing of tumor cells by anticancer therapies commonly used in the treatment of cancer, e.g. chemotherapy, γ-irradiation, immunotherapy or suicide gene therapy, is predominantly mediated by triggering cell death pathways including apoptosis in cancer cells. Thus, failure to undergo apoptosis may result in treatment resistance of cancers. Understanding the molecular events that regulate apoptosis in response to anticancer therapy and how cancer cells evade apoptotic cell death, provides novel perspectives for a more rational approach to develop molecular targeted therapies for combating cancer.
Export Options
About this article
Cite this article as:
Fulda Simone and Debatin Klaus-Michael, Apoptosis Signaling Pathways in Anticancer Therapy, Current Cancer Therapy Reviews 2008; 4 (1) . https://dx.doi.org/10.2174/157339408783565510
DOI https://dx.doi.org/10.2174/157339408783565510 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Astrocyte Signaling and Multiple Sclerosis
Current Signal Transduction Therapy Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Anti-Cancer Agents in Medicinal Chemistry Targeted Toxins for Glioblastoma Multiforme: Pre-Clinical Studies and Clinical Implementation
Anti-Cancer Agents in Medicinal Chemistry Imidazoles and Benzimidazoles as Tubulin-Modulators for Anti-Cancer Therapy
Current Medicinal Chemistry Metabotropic Purinergic Receptors in Lipid Membrane Microdomains
Current Medicinal Chemistry Enzyme-responsive Nanoparticles for Anticancer Drug Delivery
Current Nanoscience The Tumor Stroma as Mediator of Drug Resistance - A Potential Target to Improve Cancer Therapy?
Current Pharmaceutical Biotechnology Anticancer α-Helical Peptides and Structure / Function Relationships Underpinning Their Interactions with Tumour Cell Membranes
Current Protein & Peptide Science Design, Synthesis and Evaluation of Quinoline-based Small Molecule Inhibitor of STAT3
Letters in Drug Design & Discovery Curcumin: A Promising Agent Targeting Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Resistance to Peloruside A and Laulimalide: Functional Significance of Acquired βI-tubulin Mutations at Sites Important for Drug-Tubulin Binding
Current Cancer Drug Targets Kinins and Cardiovascular Diseases
Current Pharmaceutical Design Amplicons as Vaccine Vectors
Current Gene Therapy Gene Therapy and Biologic Therapy with Interleukin?4
Current Gene Therapy Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: The Kynurenine and Melatonergic Pathways in Psychiatric and CNS Disorders)
Current Pharmaceutical Design Attenuated Oncolytic Measles Virus Strains as Cancer Therapeutics
Current Pharmaceutical Biotechnology DNA Double Strand Breaks Repair Inhibitors: Relevance as Potential New Anticancer Therapeutics
Current Medicinal Chemistry Oligonucleotides and G-quadruplex Stabilizers: Targeting Telomeres and Telomerase in Cancer Therapy
Current Pharmaceutical Design Notch Inhibitors as a New Tool in the War on Cancer: A Pathway to Watch
Current Pharmaceutical Biotechnology